Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this qualitative study are to elicit concepts about symptoms that are important to patients with primary sclerosing cholangitis (PSC), as well as the key impacts of symptoms on patients' day-to-day functioning.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

NCT02932449

Biliary Cirrhosis, Primary

COMPLETED

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460

Primary Sclerosing Cholangitis

COMPLETED PHASE2

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

NCT04060147

Primary Sclerosing Cholangitis Compensated Cirrhosis

TERMINATED PHASE1

Primary Sclerosing Cholangitis in Children

NCT04181138

Primary Sclerosing Cholangitis Liver Diseases Cholangitis, Sclerosing

RECRUITING

Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis

NCT06865924

PSC

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Step I, concept elicitation one-on-one interviews (via telephone or in person) will be conducted. The aims of the concept elicitation interviews are to:

1. Identify the most common symptoms, as well as the most important symptoms, for patients with PSC, and
2. Assess whether these symptoms impact day-to-day functioning

An instrument will be developed based on the symptoms reported and in Step II of the study, the performance of the instrument will be assessed with further interviews.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Sclerosing Cholangitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Concept elicitation interviews (Step I)

Approximately 20 participants will be included.

No interventions assigned to this group

Cognitive interviews (Step II)

Approximately 30 participants will be included.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of PSC based on liver biopsy or diagnostic imaging, with diagnosis made at least three months prior to screening
* Patient report of PSC symptoms associated with PSC diagnosis
* Able to speak, read, and understand English
* Willing and able to provide written informed consent to participate in the research study

Exclusion Criteria

* Patients with other causes of liver or biliary disease, including viral hepatitis, alcoholic liver disease, primary biliary cirrhosis, and secondary sclerosing cholangitis
* Patient with history of liver cirrhosis
* Patients with history of cholangiocarcinoma
* Patients who have received a liver transplant
* Patients currently enrolled in PSC clinical trials; and
* STEP II ONLY: Enrolled in or participated in Step I of this study (concept elicitation)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No